Stock Analysis, Dividends, Split History

HLI / Houlihan Lokey, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,642.71
Enterprise Value ($M)1,530.95
Book Value ($M)819.36
Book Value / Share23.91
Price / Book2.00
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding2 35,709,520
Common Shares Outstanding 31,171,497
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.20
Return on Assets (ROA)0.12
Return on Equity (ROE)0.24
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Contracts Revenue963,364,000.00
Reimbursement Revenue30,200,000.00
Revenue From Related Parties3,006,000.00
Operating Income214.45
Net Income172.28
Earnings Per Share Diluted2.60
Earnings Per Share Basic2.76
Cash Flow Statement (mra) ($M)
Cash From Operations250.65
Cash from Investing-218.58
Cash from Financing-218.58
Identifiers and Descriptors
Central Index Key (CIK)1302215
Related CUSIPS
441593950 441593900

Split History

Stock splits are used by Houlihan Lokey, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="

Related News Stories

Orix Corporation (IX) Q1 2019 Results - Earnings Call Transcript

2018-07-30 seekingalpha
Good evening, ladies and gentlemen. Thank you for joining this telephone conference of ORIX Corporation for First Quarter Consolidated Financial Results for Three Months Period Ended June 30, 2018. The attendees at today’s conference are Executive Officer and Head of Treasury and Accounting Headquarters, Mr. Yano. Mr. Yano will give you a presentation on the third quarter financial results for about 20 minutes, and we will move it to a Q&A session. (3-0)

Houlihan Lokey's (HLI) CEO Scott Beiser on Q1 2019 Results - Earnings Call Transcript

2018-07-27 seekingalpha
Good day, ladies and gentlemen. Thank you for standing by. Welcome to Houlihan Lokey's First Quarter Fiscal 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Please note that this conference call is being recorded today July 26, 2018. (2-0)

Houlihan Lokey 2019 Q1 - Results - Earnings Call Slides

2018-07-27 seekingalpha
The following slide deck was published by Houlihan Lokey in conjunction with their 2019 Q1 earnings call. (2-0)

Zacks Market Edge Highlights: Walmart, Amazon, Netflix, Spotify and Facebook

2018-07-26 zacks
Chicago, IL – July 26, 2018 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: ( (8-0)

Seadrill: Post-Restructuring Analysis

2018-07-26 seekingalpha
I’ve been following the Seadrill (SDRL) restructuring story for many months. Ironically, the company’s emergence from Chapter 11 corresponded with my vacation, but now I had the time to reflect on both what happened with the “previous Seadrill” and also think about the “new Seadrill”. (53-0)

Silicon Investor Message Boards

This table lists all message boards related to HLI / Houlihan Lokey, Inc. on message board site Silicon Investor.

EARTHLINK (ELNK) EARTHLINK (ELNK) EARTHLINK (ELNK) HLNT - HighLine Technical Innovations, Inc HLNT - HighLine Technical Innovations, Inc HLNT - HighLine Technical Innovations, Inc
ELNK: EarthLink, Inc. ELNK: EarthLink, Inc. ELNK: EarthLink, Inc. Harmonic Lightwaves (HLIT) Harmonic Lightwaves (HLIT) Harmonic Lightwaves (HLIT)
SI Highlights SI Highlights SI Highlights HLIT: Harmonic, Inc. HLIT: Harmonic, Inc. HLIT: Harmonic, Inc.
Hartford Life HLI Hartford Life HLI Hartford Life HLI CSCO MSPG FDC JVLN Net Articles, Reader Highlight TD CSCO MSPG FDC JVLN Net Articles, Reader Highlight TD CSCO MSPG FDC JVLN Net Articles, Reader Highlight TD
HLIS - Associated with HEAL HLIS - Associated with HEAL HLIS - Associated with HEAL HLIS - HALIS, INC HLIS - HALIS, INC HLIS - HALIS, INC
CUSIP: 441593100